McLendon Lab Memo: TMS #65 - Flow Cytometric Evaluation of Patients Receiving Cell-Depleting Therapies

Recent regulatory activities within the FDA and CMS, related to laboratory-developed tests and quality-control requirements, have prompted a review of current flow cytometric tests for patients receiving cell-depleting therapies such as Thymoglobulin and Rituximab.

Please read the memo (TMS #65) for complete details.

Filed under: